stockportfolio.pro
Omeros Corporation (OMER)
Healthcare · Biotechnology · NasdaqGM
Omeros Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.62M | $64.83M | $29.87M | $111.81M | $73.81M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $40.20M | $63.75M | $29.36M | $110.94M | $72.91M | — | — | — | — | — |
| Net income | $-66.75M | $-53.48M | $-126.76M | $-84.49M | $-138.06M | $194.24M | $47.42M | $-117.81M | $-156.81M | $-3.35M |
| Net margin | -160.4% | -82.5% | -424.4% | -75.6% | -187.0% | — | — | — | — | — |
Source: Omeros Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Omeros Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OMER in your portfolio →
Omeros Corporation financial history by metric
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation — frequently asked questions
What is Omeros Corporation's revenue?
Omeros Corporation (OMER) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Omeros Corporation profitable?
No — OMER reported a net loss of $-3.35M in fiscal 2025.
What is OMER's P/E ratio?
Omeros Corporation trades at a price-to-earnings ratio of about 9.0 based on the latest data in our nightly-refreshed cache.
How much debt does Omeros Corporation have?
As of fiscal year 2025, OMER carried roughly $225.60M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Omeros Corporation's market cap?
Omeros Corporation (OMER) has a market capitalization of about $743.29M, based on the latest data in our nightly-refreshed cache.
When does Omeros Corporation's fiscal year end?
OMER's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Omeros Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.